Stason Pharmaceuticals Corporate Overview

Stason entered the commercial generic market in 1994 and today continues to manufacture and market these products through our global network of distributors. Stason entered the contract manufacturing arena in 2000 to provide manufacturing support to other pharmaceutical companies. We provide both non-high containment and high containment manufacturing services.

In 2008, we launched our Brand Division when we obtained exclusive development and commercialization rights to two novel proprietary compounds in the area of oncology. Both products are under early stage development.

In 2009, to expand our portfolio of products, Stason entered into an agreement with an overseas pharmaceutical company to represent their proprietary products in North America. Through this agreement we will select specific products to develop internally, and at the same time, identify partners to co-develop/sub-license the remaining products.

Headquartered in Southern California, the Stason group employs approximately 120 people worldwide. We have R&D and manufacturing facilities in California, USA, and Taiwan. Additional R&D facilities are located in Massachusetts, USA, and China. Our licensing offices are located in California, USA and Tokyo, Japan.